From Dealroom · · 50s
VeraDermics Raises $472M Post-IPO Equity
VeraDermics' hair-loss drug IPO soars 567% as company raises $472 million in post-IPO equity.
In brief
VeraDermics' hair-loss drug IPO soars 567% as company raises $472 million in post-IPO equity. VeraDermics raised $472 million in post-IPO equity after its hair-loss drug IPO surged 567% in 2026. Originally reported by Dealroom.
Quick answers
- What's the deal?
- VeraDermics, a clinical-stage biotech developing an oral treatment for pattern hair loss, raised $472 million in a post-IPO equity round announced in May 2026.
- Why now?
- The company listed before its Phase 3 clinical trial data landed to build capital and attract investors for a potential public entrance.
- What is the key takeaway from VeraDermics Raises $472M Post-IPO Equity?
- VeraDermics raised $472 million in post-IPO equity after its hair-loss drug IPO surged 567% in 2026.
What's the deal?
VeraDermics, a clinical-stage biotech developing an oral treatment for pattern hair loss, raised $472 million in a post-IPO equity round announced in May 2026.
Why now?
The company listed before its Phase 3 clinical trial data landed to build capital and attract investors for a potential public entrance.
“build capital”
By the numbers
Shares doubled on the February 4 debut and were up 567% as of October 14, the highest percentage return of any 2026 IPO.
“567%”
The endgame
VeraDermics has one drug candidate, VDPHL01, an oral, non-hormonal extended-release formulation of minoxidil for both men and women.
“VDPHL01”
The short version
VeraDermics raised $472 million in post-IPO equity after its hair-loss drug IPO surged 567% in 2026.
